Intrinsiqq
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc Dividend Analysis

KNSA

⊜ Compare
Dividend0
No active dividend

This company has no dividend history.

Based on TTM and annual data · Not a buy/sell signal

This company does not pay dividends

No dividend history found in SEC filings.

Does Kiniksa Pharmaceuticals International (KNSA) pay a dividend?

Kiniksa Pharmaceuticals International (KNSA) has never paid a dividend. The business does generate free cash flow of $197 million, so the absence of a dividend is a capital-allocation choice rather than an inability to pay. All figures are computed from company filings; this is analysis, not investment advice.

Frequently asked

Does Kiniksa Pharmaceuticals International (KNSA) pay a dividend?+

No. Kiniksa Pharmaceuticals International (KNSA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.

How does Kiniksa Pharmaceuticals International return cash to shareholders?+

It largely does not. Kiniksa Pharmaceuticals International pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.

Could Kiniksa Pharmaceuticals International afford to pay a dividend?+

On the numbers, yes. Kiniksa Pharmaceuticals International generated $197 million of free cash flow, which is about $2.32 per share. If it paid out half of that, the dividend would be roughly $1.16 per share, a yield of about 1.2% at the current price. That is an illustration of capacity, not a prediction: the company has given no indication it intends to pay one.

Which healthcare companies do pay dividends?+

Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Kiniksa Pharmaceuticals International.

SourceDividend analysis computed from the 10-Q filed 27 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 28 Oct 2026. How this is calculated.

Fiscal year ends Dec. Earnings payout = dividends / net income. FCF payout = dividends / FCF. Yield = TTM DPS / price.

Peers

Pharmaceutical Preparations · Pick stocks to compare with KNSA

CompareIntrinsic value
HRMYHarmony Biosciences Holdings, Inc.
$34.42-7.04%82
ANIPAni Pharmaceuticals Inc.
$72.89+0.84%85
PTCTPTC Therapeutics, Inc.
$68.97+1.25%65
IONSIonis Pharmaceuticals, Inc.
$40.15-0.67%39
CORTCorcept Therapeutics Incorporated
$77.59-5.30%56
SUPNSupernus Pharmaceuticals Inc.
$28.21+0.21%44
COLLCollegium Pharmaceutical Inc.
$23.56-0.72%98
TGTXTG Therapeutics, Inc.
$61.63+1.45%57

Held by ETFs

KNSA is in 54 US ETFs. The largest of them, with KNSA's weight in each:

Spot a number that looks wrong? Check it in KNSA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing KNSA

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.